#LPCN_1154
LightNews LightNews
newsen.bsky.social
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression
Lipocine has announced the initiation of the BLOOM Phase 3 study for LPCN 1154, targeting postpartum depression treatment with promising oral therapies.
third-news.com
September 14, 2026 at 12:17 PM
newsen.bsky.social
The Future of Postpartum Depression Treatments: Emerging Trends and Opportunities (2026-2036)#None#LPCN_1154#postpartum_depression#Luvesilocin
The Future of Postpartum Depression Treatments: Emerging Trends and Opportunities (2026-2036)
As awareness and treatment options for postpartum depression grow, innovative therapies promising rapid relief are emerging, reshaping the market landscape.
third-news.com
August 25, 2026 at 2:35 PM
newsen.bsky.social
Lipocine Reports Financial Performance and Clinical Developments for Q2 2026#United_States#Salt_Lake_City#Lipocine#LPCN_1154#BRLIZIO
Lipocine Reports Financial Performance and Clinical Developments for Q2 2026
Lipocine Inc. presents its financial results for Q2 2026 along with crucial updates on its clinical developments, particularly LPCN 1154.
third-news.com
August 4, 2026 at 12:10 PM
newsen.bsky.social
Lipocine's LPCN 1154 Phase 3 Results to Be Featured at 2026 ASCP Annual Meeting#United_States#Miami#Lipocine#LPCN_1154#ASCP_Meeting
Lipocine's LPCN 1154 Phase 3 Results to Be Featured at 2026 ASCP Annual Meeting
Lipocine's LPCN 1154 Phase 3 clinical trial results will be shared at the upcoming 2026 ASCP Annual Meeting, addressing postpartum depression.
third-news.com
May 19, 2026 at 12:40 PM
newsen.bsky.social
Lipocine Inc. Reports First Quarter Financial Results and Updates on LPCN 1154 Developments as of 2026#United_States#Salt_Lake_City#Lipocine#LPCN_1154#TLANDO
Lipocine Inc. Reports First Quarter Financial Results and Updates on LPCN 1154 Developments as of 2026
Lipocine Inc. has released its financial results for Q1 2026, highlighting LPCN 1154's clinical trial outcomes and ongoing partnerships as it navigates future developments.
third-news.com
May 7, 2026 at 8:20 PM
newsen.bsky.social
Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial
Lipocine Inc.'s Phase 3 trial results for LPCN 1154 in postpartum depression reveal mixed efficacy and a well-tolerated safety profile among participants.
third-news.com
April 2, 2026 at 12:42 PM
newsen.bsky.social
Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities#United_States#Salt_Lake_City#Lipocine#LPCN_1154#TLANDO
Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities
Lipocine Inc. shared its financial results for 2025, showcasing significant pipeline developments for mental health and metabolic disorders, setting the stage for future progress.
third-news.com
March 10, 2026 at 12:43 PM
newsen.bsky.social
Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment
Lipocine Inc. completes the last patient visit in the Phase 3 trial of LPCN 1154, an oral treatment for postpartum depression (PPD), showing positive safety results.
third-news.com
February 18, 2026 at 1:22 PM
newsen.bsky.social
Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression
Lipocine has finished participant enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. Initial results are promising.
third-news.com
January 20, 2026 at 1:39 PM
newsen.bsky.social
Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review
Lipocine Inc. announced the successful completion of an independent safety review for LPCN 1154 in a Phase 3 trial targeting postpartum depression, reinforcing confidence in its efficacy.
third-news.com
January 12, 2026 at 1:14 PM
newsen.bsky.social
Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment#USA#Salt_Lake_City#Lipocine#LPCN_1154#PPD_Treatment
Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment
Lipocine Inc. has achieved 80% enrollment in its Phase 3 clinical trial for LPCN 1154, an innovative treatment for postpartum depression (PPD).
third-news.com
December 16, 2025 at 1:27 PM
newsen.bsky.social
Lipocine Reports Q3 2025 Financial Results and Clinical Updates#USA#Salt_Lake_City#Lipocine#LPCN_1154#TLANDO
Lipocine Reports Q3 2025 Financial Results and Clinical Updates
Lipocine Inc. announces third quarter financial results for 2025 and updates on clinical trials, including LPCN 1154 for postpartum depression.
third-news.com
November 6, 2025 at 1:25 PM
newsen.bsky.social
Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression
Lipocine Inc. shares an update on its Phase 3 trial of LPCN 1154 for postpartum depression, with promising enrollment and safety review plans.
third-news.com
September 30, 2025 at 12:18 PM
newsen.bsky.social
Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies#USA#Salt_Lake_City#Lipocine#LPCN_1154#TLANDO
Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies
Lipocine Inc. shares Q2 financial results and advancements on LPCN 1154, a treatment for postpartum depression, alongside updates on LPCN 2401.
third-news.com
August 5, 2025 at 12:25 PM
newsen.bsky.social
Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025
Join Lipocine's virtual R&D investor event on July 9, 2025, to explore LPCN 1154's potential in treating postpartum depression, alongside expert insights.
third-news.com
June 23, 2025 at 12:22 PM
newsen.bsky.social
Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025#United_States#Salt_Lake_City#LPCN_1154#TLANDO#Lipocine_Inc
Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025
Lipocine Inc. announces its financial performance for Q1 2025, highlighting key developments and ongoing studies towards innovative treatments.
third-news.com
May 8, 2025 at 12:24 PM
newsen.bsky.social
Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression
Lipocine Inc. has launched a Phase 3 trial for LPCN 1154, aimed at treating postpartum depression through effective oral delivery.
third-news.com
March 26, 2025 at 12:33 PM
newsen.bsky.social
Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression#USA#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression
Lipocine's latest regulatory guidance suggests further safety and efficacy trials for LPCN 1154, aiming to address postpartum depression in women rapidly.
third-news.com
February 6, 2025 at 1:07 PM